Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$480.73 USD
+1.70 (0.35%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $480.85 +0.12 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 261 - 280 ( 329 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Our Thoughts on the Dynamic CF Landscape: ENaC inhibitors, Resolvins, and HDACs
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
809 Shades Darker: Our Thoughts on the Orkambi* AdCom
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Thinking Through and Beyond the Second-Generation Corrector Paradigm
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Update from the European CF Basic Science Conference
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The More Things Change, the More They Stay the Same
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended March 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Year Ahead: VX-809 Launch and Accretive Business Development to Set Course
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
$15M Down, $3.285B To Go: We Look at Shire?s Approach to CF Therapy Following Grant from CF Foundation Therapeutics
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
3Q14 Update: Our Thoughts on Lumacaftor in 2015 and Kalydeco in Australia
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Technical Analysis - Biotech Stocks Ignored and Oversold, Offering Good Entry
Provider: Drexel Hamilton, LLC
Analyst: SINE B